Download PDF
Thromb Haemost 2014; 112(02): 424-425
DOI: 10.1160/TH13-12-1045
Letters to the Editor
Schattauer GmbH

Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect

Massimo Morfini
1   Agency for Hemophilia and Regional Reference Center for Inherited Bleeding Disorders, Azienda Ospedaliariero – Universitaria Careggi, Florence, Italy
,
Angelika Batorova
2   The National Haemophilia Centre, Institute of Haematology and Blood Transfusion LFUK, University Hospital, Bratislava, Slovakia
,
Guglielmo Mariani
3   Department of Life Sciences and Biotechnology, University of Ferrara, Medical School, Ferrara, Italy
,
Günter Auerswald
4   Klinikum Bremen-Mitte, Professor Hess Children’s Hospital, Bremen, Germany
,
Francesco Bernardi
3   Department of Life Sciences and Biotechnology, University of Ferrara, Medical School, Ferrara, Italy
,
Giovanni Di Minno
5   Department of Clinical and Experimental Medicine, Federico II University, Naples, Italy
,
Alberto Dolce
6   National Institute of Statistics, Palermo, Italy
,
Calogero Fede
6   National Institute of Statistics, Palermo, Italy
,
Muriel Giansily-Blaizot
7   Laboratory of Hematology, University Hospital, Montpellier, France
,
Jörgen Ingerslev
8   Centre for Hemophilia and Thrombosis, Aarhus University Hospital, Skejby, Aarhus, Denmark
,
Uri Martinowitz
9   National Hemophilia Center, Chaim Sheba Medical Center, Tel Hashomer, and Sackler School of Medicine, Tel Aviv University, Israel
,
Mariasanta Napolitano
10   University of Palermo, Haematology Unit, Thrombosis and Hemostasis Reference Regional Center, Palermo, Italy
,
Mirko Pinotti
3   Department of Life Sciences and Biotechnology, University of Ferrara, Medical School, Ferrara, Italy
,
Jean-Francois Schved
7   Laboratory of Hematology, University Hospital, Montpellier, France
,
for the International FVII [IF7] and Seven Treatment Evaluation Registry [STER] Study Groups › Author Affiliations Financial support: Editorial assistance was provided by Anne Stirland (PAREXEL) and was financially supported by Novo Nordisk in compliance with international guidelines for good publication practice. MM, GM, FB and MP wish to acknowledge the AIFA grant (Progetto RF-null-2008–1235892).
Further Information

Publication History

Received: 20 December 2013

Accepted after minor revision: 11 March 2014

Publication Date:
04 December 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Berrettini M, Mariani G, Schiavoni M. et al. Pharmacokinetic evaluation of recombinant, activated factor VII in patients with inherited factor VII deficiency. Haematologica 2001; 86: 640-645.
    PubMedGoogle Scholar
  • 2 Mathijssen NCJ, Masereeuw R, Holme PA. et al. Increased volume of distribution for recombinant activated factor VII and longer plasma-derived factor VII half-life may explain their long lasting prophylactic effect. Thromb Res 2013; 132: 256-262.
    CrossrefPubMedGoogle Scholar
  • 3 Mathijssen NC, Masereeuw R, Verbeek K. et al. Prophylactic effect of recombinant factor VIIa in factor VII deficient patients. Br J Haematol 2004; 125: 494-499.
    CrossrefPubMedGoogle Scholar
  • 4 Napolitano M, Giansily-Blaizot M, Dolce A. et al. Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER). Haematologica 2013; 98: 538-544.
    CrossrefPubMedGoogle Scholar